Advanced search
Publication Cover
Expert Review of Medical Devices Volume 7, 2010 - Issue 5
Submit an article Journal homepage
50
Views
4
CrossRef citations to date
0
Altmetric
Review

The comparative safety of bare-metal and drug-eluting intracoronary stents

Nathan D Lambert Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston–Salem, NC 27157-21045, USA; Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston–Salem, NC 27157-21045, USA
&
Robert J Applegate Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston–Salem, NC 27157-21045, USA;[email protected]
Pages 611-624 | Published online: 09 Jan 2014

References

  • Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N. Engl. J. Med.354, 483–495 (2006).
  • Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol.40, 2082–2089 (2002).
  • Holmes DR Jr, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation109, 634–640 (2004).
  • Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation109, 1942–1947 (2004).
  • Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation119, e21–e181 (2009).
  • Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart92, 641–649 (2006).
  • Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation103, 1967–1971 (2001).
  • Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am. J. Med.119, 1056–1061 (2006).
  • McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet364, 1519–1521 (2004).
  • Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol.45, 2088–2092 (2005).
  • Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation112, 270–278 (2005).
  • Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation108, 1701–1706 (2003).
  • Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369, 667–678 (2007).
  • Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med.356, 998–1008 (2007).
  • Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA293, 2126–2130 (2005).
  • Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol.48, 2584–2591 (2006).
  • Lagerqvist B, James SK, Stenestrand U et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med.356, 1009–1019 (2007).
  • Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents. A cause for concern. Circulation115, 1440–1455 (2007).
  • Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation115, 2344–2351 (2007).
  • Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N. Engl. J. Med.356, 984–987 (2007).
  • Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation120, 391–399 (2009).
  • Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation115, 2435–2441 (2007).
  • Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48, 193–202 (2006).
  • Awata M, Kotani J, Uematsu M et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation116, 910–916 (2007).
  • Kotani J, Awata M, Nanto S et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol.47, 2108–2111 (2006).
  • Chen BX, Ma FY, Luo W et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart94, 566–570 (2008).
  • Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation104, 600–605 (2001).
  • Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation109, 701–705 (2004).
  • Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol.47, 175–181 (2006).
  • Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation105, 2974–2980 (2002).
  • Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J. Am. Coll. Cardiol.35, 157–163 (2000).
  • Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation115, 2426–2434 (2007).
  • Alfonso F, Perez-Vizcayno MJ, Ruiz M et al. Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J. Am. Coll. Cardiol.53, 2053–2060 (2009).
  • Tanabe K, Serruys PW, Degertekin M et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: Insights from the randomized TAXUS II trial. Circulation111, 900–905 (2005).
  • Hoffman R, Morice MC, Moses JW et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart94, 322–328 (2008).
  • Hong MK, Mintz GS, Lee CW et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation113, 414–419 (2006).
  • Hassan AKM, Bergheanu SC, Stijnen T et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation with associates with late stent thrombosis. Euro. Heart J.31(10), 1172–1180 (2009).
  • Ueno K, Kawamura A, Mintz GS et al. Progression of late stent malapposition beyond 2 years after sirolimus-eluting stent implantation. J. Am. Coll. Cardiol. Intv.2, 1288–1289 (2009).
  • Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drug-eluting stents. Cathet. Cardiovasc. Intervent.68, 83–88 (2006).
  • Nakazawa G, Finn AV, Vorpahl M et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery: a pathologic analysis. J. Am. Coll. Cardiol.54, 1924–1931 (2009).
  • Carter AJ. Drug-eluting stent fracture: Promise and performance (editorial comment). J. Am. Coll. Cardiol.54, 1932–1934 (2009).
  • Doi H, Maehara A, Mintz GS et al. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am. J. Cardiol.103, 818–823 (2009).
  • Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Cathet. Cardiovasc. Intervent.69, 380–386 (2007).
  • Chung WS, Park CS, Seung KB et al. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Internatl. J. Card.125, 325–331 (2008).
  • Lee SH, Park JS, Shin DG et al. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. Am. J. Cardiol.100, 627–630 (2007).
  • Jin X, Zhang S, Xie H et al. Strut fracture of DES: An increasing problem? (letter to editor). Internatl. J. Card.118, e54–e56 (2007).
  • Chhatriwalla AK, Cam A, Unzek S et al. Drug-eluting stent fracture and acute coronary syndrome. Cardio. Revasc. Med.10, 166–171 (2009).
  • O’Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomaterialia5, 945–958 (2009).
  • Doyle B, Rihal CS, O’Sullivan CJ et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation116, 2391–2398 (2007).
  • van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J. Am. Coll. Cardiol.53, 1399–1409 (2009).
  • Roy P, Bonello L, Torguson R et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am. J. Cardiol.103, 801–805 (2009).
  • Yan BP, Duffy SJ, Clark DJ et al. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am. J. Cardiol.101, 1716–1722 (2008).
  • Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol.98, 352–356 (2006).
  • Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohort registry. J. Am. Coll. Cardiol.50, 501–508 (2007).
  • Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation113, 1108–1113 (2006).
  • Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation116, 745–754 (2007).
  • Park DW, Yun SC, Lee SW et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. Intv.1, 494–503 (2008).
  • Schulz S, Schuster T, Mehilli J et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J.30, 2714–2721 (2009).
  • Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349, 1315–1323 (2003).
  • Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350, 221–231 (2004).
  • Smith SC Jr, Feldman TE, Hirshfield JW Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol.47, 216–235 (2006).
  • Kushner FG, Hand M, Smith SC Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.54, 2205–2241 (2009).
  • Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357, 2001–2015 (2007).
  • Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, for the CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am. Heart J.157, 369–374 (2009).
  • Caixeta A, Leon MB, Lansky AJ et al. 5-year clinical outcomes after sirolimus-eluting stent implantation: insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol.54, 894–902 (2009).
  • Ellis SG, Stone GW, Cox DA et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of de novo coronary disease using a single paclitaxel-eluting stent). J. Am. Coll. Cardiol. Intv.2, 1248–1259 (2009).
  • Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur. Heart J.30, 16–24 (2009).
  • James SK, Stenestrand U, Lindback J et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N. Engl. J. Med.360, 1933–1945 (2009).
  • Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation119, 3198–3206 (2009).
  • Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet370, 937–948 (2007).
  • Applegate RJ, Sacrinty MT, Kutcher MA et al. ‘Off-Label’ stent therapy: 2-year comparison of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol.51, 607–614 (2008).
  • Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. 3-year comparison of drug-eluting stents versus bare metal stents. J. Am. Coll. Cardiol. Intv.2, 231–239 (2009).
  • Schwalm JDR, Ahmad M, Velianou JL, Xie C, Natarajan MK. Primary and rescue percutaneous coronary intervention with paclitaxel-eluting stent implantation in ST-elevation myocardial infarction. Am. J. Cardiol.97, 1308–1310 (2006).
  • Briguori C, Colombo A, Airoldi F et al. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am. Heart J.150, 807–813 (2005).
  • Daemen J, Kuck KH, Macaya C et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (arterial revascularization therapies study-part II) trial. J. Am. Coll. Cardiol.52, 1957–1967 (2008).
  • Kelbaek H, Thuesen L, Helqvist S et al. The stenting coronary arteries in non-stress/benestent disease (SCANDSTENT) trial. J. Am. Coll. Cardiol.47, 449–455 (2006).
  • Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation118, 1138–1145 (2008).
  • Brar SS, Leon MB, Stone GW et al. Use of drug-eluting stents in acute myocardial infarction. J. Am. Coll. Cardiol.53, 1677–1689 (2009).
  • Brilakis ES, Lichtenwalter C, de Lemos JA et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions. J. Am. Coll. Cardiol.53, 919–928 (2009).
  • Vermeersch P, Agostoni P, Verheye S et al. Increased mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. J. Am. Coll. Cardiol.50, 261–267 (2007).
  • Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol.52, 1134–1140 (2008).
  • Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am. Heart J.151, 1260–1264 (2006).
  • Stone GW, Ellis SG, Colombo A et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation115, 2842–2847 (2007).
  • Mauri L, Hsieh WH, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med.356, 1020–1029 (2007).
  • Applegate RJ, Sacrinty MT, Little WC, Santos RM, Gandhi SK, Kutcher MA. Incidence of coronary stent thrombosis based on Academic Research Consortium definitions. Am. J. Cardiol.102, 683–688 (2008).
  • Byrne RA, Iijima R, Mehilli J et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J. Am. Coll. Cardiol. Intv.2, 291–299 (2009).
  • Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation119, 680–686 (2009).
  • Stone GW, Rizvi A, Newman W et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med.362, 1663–1674 (2010).
  • Latib A, Ferri L, Ielasi A et al. Clinical outcomes after unrestricted implantation of everolimus-eluting stents. J. Am. Coll. Cardiol. Intv.2, 1219–1226 (2009).
  • Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol.48, 2440–2447 (2006).
  • Eisenstein EL, Leon MB, Kandzari DE et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the Cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). J. Am. Coll. Cardiol. Intv.2, 1199–1207 (2009).
  • Leon MB, Kandzari DE, Eisenstein EL et al. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (randomized, controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions). J. Am. Coll. Cardiol. Intv.2, 1208–1218 (2009).
  • Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; for the E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry. J. Am. Coll. Cardiol. Intv.2, 1227–1235 (2009).
  • Finn AV, Vorpahl M, Ladich E, Virmani R. Future directions in stenting. Expert Rev. Cardiovasc. Ther.8, 1–6 (2010).
  • Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial. J. Am. Coll. Cardiol.41, 1283–1288 (2003).
  • Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet371, 899–907 (2008).
  • Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet373, 897–910 (2009).
  • Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. Lancet372, 1163–1173 (2008).
  • Nakazawa G, Granada JF, Alviar CL et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. J. Am. Coll. Cardiol. Intv.3, 68–75 (2010).
  • Kukreja N, Onuma Y, Garcia-Garcia HM et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. Intv.2, 534–541 (2009).
  • de la Torre-Hernandez JM, Alfonso F, Hernandez F et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol.51, 986–990 (2008).
  • Lambert ND, Sacrinty MT, Ketch TR et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am. Heart J.157, 688–694 (2009).
  • McKee SA, Applegate RJ, Hoyle JR, Sacrinty MT, Kutcher MA, Sane DC. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am. Heart J.154, 159–164 (2007).
  • Aoki J, Lansky AJ, Mehran R et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the acute catheterization and urgent intervention triage strategy trial. Circulation119, 687 (2009).
  • Liu X, Doi H, Maehara A et al. A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. J. Am. Coll. Cardiol. Intv.2, 428–434 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.